...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Dual-targeting liposomes with active recognition of GLUT(5) and alpha(v)beta(3) for triple-negative breast cancer
【24h】

Dual-targeting liposomes with active recognition of GLUT(5) and alpha(v)beta(3) for triple-negative breast cancer

机译:具有激活识别的双靶向脂质体,用于三重阴性乳腺癌的粘液(5)和α(v)β(3)

获取原文
获取原文并翻译 | 示例

摘要

At present, chemo- and radiotherapies remain to be the mainstream methods for treating triple-negative breast cancer (NBC), which is known for poor prognosis and high rate of mortality. Two types of novel dual-targeting TNBC liposomes (Fru-RGD-Lip and Fru+RGD-Lip) that actively recognize both fructose transporter GLUT(5) and integrin alpha(v)beta(3) were designed and prepared in this work. Firstly, a Y-shaped Fru-RGD-chol ligand, where a fructose and peptide Arg-Gly-Asp (RGD) were covalently attached to cholesterol, was designed and synthesized. Then, the Fru-RGD-Lip was constructed by inserting Fru-RGD-chol into liposomes, while Fru+RGD-Lip was obtained by inserting both Fru-chol and RGD-chol (with the molar ratio of 1:1) into liposomes. The particle size, zeta potential, encapsulation efficiency and serum stability of the paclitaxel-loaded liposomes were characterized. The results indicated that the paclitaxel-loaded Fru-RGD-Lip had the strongest growth inhibition against GLUT(5) and alpha(v)beta(3) overexpressed MDA-MB-231 and 4T1 cells. The cellular uptake of Fru-RGD-Lip on MDA-MB-231 cells and 4T1 cells was 3.19- and 3.23-fold more than that of the uncoated liposomes (Up). The uptake of Fru+RGD-Lip was slightly lower, giving a 2.81- and 2.90-fold increase than that of Lip in two cell lines, respectively. The mechanism study demonstrated that the cellular uptake of both dual-targeting liposomes was likely to be recognized and mediated by GLUT(5) and alpha(v)beta(3) firstly, then endocytosed through comprehensive pathways in an energy-dependent manner. Moreover, Fru-RGD-Lip displayed the maximum accumulation, which was 2.62-fold higher than that of Lip for instance, at the tumor sites compared to other liposomes using in vivo imaging. Collectively, the liposomes co-modified by fructose and RGD have enormous potential in the development of targeted NBC treatment, especially the covalently modified Fru-RGD-Lip, making it a promising multifunctional liposome. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:目前,化学和放射疗法仍然是治疗三阴性乳腺癌(NBC)的主流方法,这已知以差的预后差和高死亡率。在这项工作中设计并制备了两种类型的新型双靶向TNBC脂质体(FRU-RGD-唇和FRU + RGD-唇缘),其主动识别果糖转运蛋白(5)和整合素α(V)β(3)。首先,设计和合成了一种Y形FRU-RGD-CHOL配体,其中将果糖和肽ARG-GLY-ASP(RGD)共价连接并合成。然后,通过将FRU-RGD-CHOL插入脂质体来构建FRU-RGD-唇,而FRU + RGD-唇通过将FRU-CHOL和RGD-CHOL(具有1:1的摩尔比)插入脂质体而获得。表征了紫杉醇加载脂质体的粒度,ζ电位,封装效率和血清稳定性。结果表明,紫杉醇负载的FRU-RGD-唇缘具有对紫外线(5)和α(V)β(3)过表达的MDA-MB-231和4T1细胞的最强的生长抑制。在MDA-MB-231细胞和4T1细胞上的FRU-RGD-唇的细胞吸收为3.19-和3.23倍,比未涂覆的脂质体(UP)更多。 FRU + RGD-唇的摄取略低,分别比两种细胞系中的唇缘增加2.81-和2.90倍。该机制研究表明,双靶向脂质体的细胞吸收可能首先通过综合途径通过综合途径来识别和介导双靶向脂质体的细胞吸收,然后通过综合途径内吞。此外,与使用体内成像的其他脂质体相比,FRU-RGD-唇缘显示比例如唇缘高2.62倍。共同地,通过果糖和RGD共同修饰的脂质体在靶向NBC处理的发育中具有巨大潜力,特别是共价修饰的FRU-RGD-唇,使其成为有前途的多功能脂质体。 (c)2019年Elsevier Masson SAS。版权所有。

著录项

  • 来源
  • 作者单位

    Sichuan Univ Sichuan Res Ctr Drug Precis Ind Technol Sichuan Engn Lab Plant Sourced Drug West;

    Sichuan Univ Sichuan Res Ctr Drug Precis Ind Technol Sichuan Engn Lab Plant Sourced Drug West;

    Sichuan Univ Sichuan Res Ctr Drug Precis Ind Technol Sichuan Engn Lab Plant Sourced Drug West;

    Sichuan Univ Sichuan Res Ctr Drug Precis Ind Technol Sichuan Engn Lab Plant Sourced Drug West;

    Sichuan Univ Sichuan Res Ctr Drug Precis Ind Technol Sichuan Engn Lab Plant Sourced Drug West;

    Sichuan Univ Sichuan Res Ctr Drug Precis Ind Technol Sichuan Engn Lab Plant Sourced Drug West;

    Sichuan Univ Sichuan Res Ctr Drug Precis Ind Technol Sichuan Engn Lab Plant Sourced Drug West;

    Sichuan Univ Sichuan Res Ctr Drug Precis Ind Technol Sichuan Engn Lab Plant Sourced Drug West;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    Liposome; Dual-targeting; TNBC; Fructose; RGD peptide;

    机译:脂质体;双靶向;TNBC;果糖;RGD肽;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号